EMLA CREAM 5%

SUMMARY OF PRODUCT CHARACTERISTICS

1

NAME OF THE MEDICINAL PRODUCT
EMLA Cream 5%

2.

QUALITATIVE AND QUANTITATIVE COMPOSITION Lidocaine 2.5% w/w (25 mg/g) Prilocaine 2.5% w/w (25 mg/g) For excipients, see 6.1

3.

PHARMACEUTICAL FORM White soft cream.

4
4.1

CLINICAL PARTICULARS
Therapeutic indications

Adults: Topical anaesthesia of the skin in connection with: intact skin prior to minor dermatological procedures (e.g. needle insertion and surgical treatment of localised lesions) and prior to dermal procedures on larger areas e.g. split skin grafting. dermal procedures on newly shaven skin of large body areas e.g. laser hair removal Topical anaesthesia of the genital mucosa, e.g. prior to superficial surgical procedures or prior to infiltration anaesthesia of mucosa. Topical anaesthesia of leg ulcers to facilitate mechanical cleansing/debridement.

-

Paediatric: EMLA Cream is indicated in the following age groups: neonates 0-2 months, infants 3-11 months and children 1-11 years, for topical anaesthesia of the skin in connection

with needle insertion e.g. iv catheters or blood sampling and in superficial surgical procedure. EMLA Cream is also indicated in children with atopic dermatitis prior to curettage of mollusca. Studies have failed to demonstrate efficacy of EMLA for heel lancing in newborn infants.

4.2

Posology and method of administration
Procedure Application Apply a thick layer of cream on the skin and cover it with occlusive dressing. Approx. 1.5 g/10 cm2 Minor procedures e.g. needle insertion and surgical treatment of localised lesions. Dermal surgical procedures on larger areas in a hospital setting e.g. split skin grafting. Dermal procedures on newly shaven skin of large body areas e.g. laser hair removal (selfapplication by patient) 2 g (approx. half a 5 g tube) for 1 to 5 hours1)

Surface/ Age Skin

Adults

Approx. 1.5-2 g/10 cm2 for 2 to 5 hours1)

Maximum recommended dose: 60g. Maximum recommended treated area: 600 cm2 for a minimum of 1 hour, maximum 5 hours.1)

Children

Minor procedures, e.g. needle insertion and surgical treatment of localised lesions

Approx. 1.0 g/10 cm2 for 1 hour (see details below)

Neonates 0-2 months3) 8) Infants 3-11 months3) Children 1-5 years Children 6-11 years

Up to 1.0 g and 10 cm2 for one hour 2) Up to 2.0 g and 20 cm2 for one hour 4) Up to 10.0 g and 100 cm2 for 1-5 hours1) Up to 20.0 g and 200 cm2 for 1-5 hours1)

Children with atopic dermatitis Genital mucosa Adults

Prior to removal of mollusca.

Application time: 30 minutes

Surgical treatment of localised lesions, e.g. removal of genital warts (condylomata accuminata) and prior to injection of local anaesthetics. Prior to cervical curettage.

Approx. 5-10 g EMLA for 5-10 minutes1). No occlusive dressing is required. Commence the procedure immediately after removal of cream.

Administer 10 g of cream in lateral vaginal fornices for 10 minutes.

Skin of male genital organs Adults Skin of female genital organs Adults Leg ulcer Adults

Prior to injection of local anaesthetics Prior to injection of local anaesthetics7) Mechanical cleansing /debridement of leg ulcer(s).

Apply a thick layer of EMLA cream (1 g/10cm2) with occlusive dressing for 15 minutes Apply a thick layer of EMLA cream (1-2 g/10cm2) with occlusive dressing for 60 minutes Apply a thick layer of the cream, approx. 1-2 g/10 cm2 up to a total of 10 g to the leg ulcer(s).5, 6) Cover with an occlusive dressing. Application time: 30 to 60 minutes. Cleansing should start without delay after removal of the cream.

1) 2) 3) 4) 5) 6) 7) 8)

After a longer application time anaesthesia decreases. Application for >1 hour has not been documented. Until further clinical data are available, EMLA should not be used in infants up to 12 months of age receiving treatment with methaemoglobin-inducing agents. No clinically significant increase in plasma methaemoglobin levels has been observed after an application time of up to 4 hours on 16 cm2. EMLA has been used for the treatment of leg ulcers up to 15 times over a period of 1-2 months without loss of efficacy or increased number or severity of adverse events. Plasma levels have not been determined in patients treated with doses of >10 g, (See also Section 5.2). On female genital skin, EMLA alone applied for 60 or 90 min does not provide sufficient anaesthesia for thermocautery or diathermy of genital warts. Until further clinical data are available, EMLA should not be used at less than 37 weeks gestational age.

One gram of EMLA cream pressed out of a tube of 30 g is approximately 3.5 cm. Persons frequently applying or removing cream should ensure that contact is avoided in order to prevent the development of hypersensitivity. Paediatric population Adolescents 12 years:

As for adults (approximately 2 g EMLA applied under an occlusive dressing for a minimum of 60 minutes, maximum 5 hours). Term newborn infants, infants and children 11 years: In term newborn infants and infants < 3 months, only one single dose should be applied in any 24 hour period. For children aged 3 months and above, a maximum of 2 doses, separated by at least 12 hours can be given within any 24 hour period. If, based on clinical need, a decision is nevertheless taken to use two applications in children under the age of 3 months, see sections 4.4 and 4.8. The safety of EMLA in pre-term newborn infants has not been established. Use of EMLA is not recommended in pre-term infants. Use of EMLA is not recommended in infants less than 3 months of age receiving treatment with methaemoglobin-inducing drugs (see section 4.4). For all age groups analgesic efficacy may decline if the skin application time is more than 5 hours. Procedures on intact skin should begin soon after the occlusive dressing is removed. On the genital mucosa analgesic efficacy declines after 10-15 minutes and therefore the procedure should be commenced immediately. Methods of dose estimation EMLA is available in 5 g and 30 g tubes. To dispense 1 g of EMLA from either tube size, apply the cream to a circular area with a diameter of approx. 18 mm (a 1 pence coin) and depth of approx. 4 to 5 mm. If high levels of accuracy in dosing are required to prevent overdose (i.e. at doses approaching the maximum in neonates or if two applications may be required in a 24 h period), a syringe can be used where 1 ml = 1 g. A string of cream can be used to define the quantity of EMLA administered from the 30 g tube where 1 g = 3.5 cm; however, a string of cream may not be appropriate for all application needs, e.g. when administering a low dose to small surface areas.

4.3

Contraindications Hypersensitivity to the amide-type local anaesthetics or to any other component of the product.

4.4

Special warnings and special precautions for use EMLA should not be used in the following cases: (a) in pre-term neonates i.e. gestational age less than 37 weeks.

(b) in infants/neonates between 0 and 12 months of age receiving treatment with methaemoglobin-inducing agents due to the possible additive effects. In infants/neonates younger than 3 months a transient, clinically insignificant increase in methaemoglobin level is commonly observed up to 12 hours after an application of EMLA. Patients with defective glucose-6-phosphate dehydrogenase, hereditary or idiopathic methaemoglobinaemia are more susceptible to drug induced signs of methaemoglobinaemia. In term newborn infants, infants and children, EMLA should only be used on intact skin and should not be applied to genital mucosa. In term neonates and infants < 3 months, only one single dose should be applied in any 24 hour period. If, based on clinical need, a decision is nevertheless taken to use two applications in children under the age of 3 months, the child should be clinically monitored for systemic adverse reactions (see sections 4.8 and 4.9). Consideration should be given to the fact that pulse oximeter values may overestimate the actual oxygen saturation in case of increased methaemoglobin fraction; therefore, in cases of suspected methaemoglobinaemia, it may be more helpful to monitor oxygen saturation by co-oximetry. Care must be taken to limit the dose and area of application and to prevent accidental ingestion. Due to insufficient data on absorption of active substances, EMLA should not be applied to open wounds (excluding leg ulcers). Due to the potentially enhanced absorption on newly shaven skin, it is important to adhere to the recommended dosage, area and time of application (see Section 4.2). Studies have been unable to demonstrate the efficacy of EMLA for heel lancing in neonates. EMLA should not be applied to the genital mucosa of children owing to insufficient data on absorption of active substances. However, when used in neonates for circumcision, a dose of 1.0 g EMLA on the prepuce has been proven to be safe. Care should be taken when applying EMLA to patients with atopic dermatitis. A shorter application time, 15-30 minutes, may be sufficient (see Section 5.1). Application times of longer than 30 minutes in patients with atopic dermatitis may result in an increased incidence of local vascular reactions, particularly application site redness and in some cases petechia and purpura (see Section 4.8 Undesirable effects). Prior to removal of mollusca in children with atopic dermatitis, it is recommended to apply cream for 30 minutes.

When applied in the vicinity of the eyes, EMLA cream should be used with particular care since it may cause eye irritation. Also the loss of protective reflexes may allow corneal irritation and potential abrasion. If eye contact occurs, immediately rinse the eye with water or sodium chloride solution and protect the eye until sensation returns. EMLA should not be applied to an impaired tympanic membrane. Tests on laboratory animals have shown that EMLA cream has an ototoxic effect when instilled into the middle ear. Animals with an intact tympanic membrane, however, show no abnormality when exposed to EMLA cream in the external auditory canal. Although the systemic availability of prilocaine by percutaneous absorption of EMLA is low, caution should be exercised in patients with anaemia, congenital or acquired methaemoglobinaemia or patients on concomitant therapy known to produce such conditions. Patients treated with anti-arrhythmic drugs class III (eg, amiodarone) should be carefully monitored and ECG monitoring considered as cardiac effects may be additive. Lidocaine and prilocaine have bacteriocidal and antiviral properties in concentrations above 0.5 2%. For this reason, although one clinical study suggests that the immunization response, as assessed by local wheal formation, is not affected when EMLA Cream is used prior to BCG vaccination, the results of intracutaneous injections of live vaccines should be monitored. EMLA Cream contains polyoxyethylene hydrogenated castor oil which may cause skin reactions. 4.5 Interaction with other medicinal products and other forms of interaction

Prilocaine in high doses may cause an increase in methaemoglobin plasma levels particularly in conjunction with methaemoglobin-inducing agents, e.g. sulphonamides, acetanilid, aniline dyes, benzocaine, chloroquine, dapsone, metoclopramide, naphthalene, nitrates and nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine, para-aminosalicylic acid, phenacetin, phenobarbital, phenytoin, primaquine, quinine. With large doses of EMLA, consideration should be given to the risk of additional systemic toxicity in patients receiving other local anaesthetics or agents structurally related to local anaesthetics, since the toxic effects are additive. Specific interaction studies with lidocaine/prilocaine and anti-arrhythmic drugs class III (eg, amiodarone) have not been performed, but caution is advised (see also Section 4.4). Drugs that reduce the clearance of lidocaine (eg, cimetidine or betablockers) may cause potentially toxic plasma concentrations when lidocaine is given in repeated high doses over a long time period. Such interactions should therefore be of no clinical

importance following short-term treatment with lidocaine (eg, EMLA cream) at recommended doses. 4.6 Pregnancy and lactation Animal studies do not indicate any direct or indirect harmful effects on pregnancy, embryo-foetal development, parturition or postnatal development. Pregnancy Lidocaine and prilocaine cross the placental barrier and may be absorbed by the foetal tissues. It is reasonable to assume that lidocaine and prilocaine have been used in a large number of pregnant women and women of childbearing age. No specific disturbances to the reproductive process have so far been reported, e.g. an increased incidence of malformations or other directly or indirectly harmful effects on the foetus. However caution should be exercised when used in pregnant women. Lactation Lidocaine and, in all probability, prilocaine are excreted in breast milk, but in such small quantities that there is generally no risk of the child being affected at therapeutic dose levels. 4.7 Effects on ability to drive and use machines
EMLA has no influence on driving ability and the ability to operate machines when used at the recommended doses.

4.8

Undesirable effects

Common (>1/100)

Skin

Transient local reactions at the application site such as paleness, erythema (redness) and oedema.
1,2,3)

Uncommon (1/1000 to 1/100)

Skin

Rare (<1/1000)

General

An initial and usually mild sensation of burning, itching or warmth at the application site2,3) An initial mild burning, itching sensation or warmth at the application site1) Local paresthesia at the application site, e.g. tingling sensation2) Skin irritation at the application site3) Methaemoglobinaemia.1) Rare cases of discrete local lesions at site of administration such as purpuric or petechial, especially at longer application time in children with atopic dermatitis or mollusca contagiosa1) Corneal irritation after accidental eye exposure1) In rare cases, local anaesthetic preparations have been associated with allergic reactions (in the most severe cases anaphylactic shock)1,2,3)

1) Intact skin 2) Genital Mucosa 3) Leg ulcer Paediatric population In clinical trials 298 neonates and infants aged up to 12 months were treated with EMLA (Table 3). A large number of infants and children aged 1 year and older have been treated with EMLA in clinical trials and in clinical practice since 1984. Table 3. Number of paediatric patients, up to 12 months old, included in clinical studies with EMLA, by age group

Group Pre-term neonates Age 01 months Age 13 months Age 312 months Total number

Number of patients 21 148 55 74 298

Frequency, type and severity of adverse reactions are similar in the paediatric and adult age groups, except for methaemoglobinaemia, which is more frequently observed, often in connection with overdose, in neonates and infants aged 0 to 12 months. Rare cases of clinically significant methaemoglobinaemia in children have been reported in literature. Prilocaine, one of the components of EMLA, may in high doses cause an increase in the methaemoglobin level, particularly in susceptible individuals (Section 4.4) and in conjunction with other methaemoglobin-inducing agents. Clinically significant methaemoglobinaemia should be treated with a slow intravenous injection of methylthioninium chloride (Section 4.9). 4.9 Overdose Rare cases of clinically significant methaemoglobinaemia have been reported. Prilocaine in high doses may cause an increase in the methaemoglobin plasma levels particularly in conjunction with methaemoglobin-inducing agents (e.g. sulphonamides). Clinically significant methaemoglobinaemia should be treated with a slow intravenous injection of methylene blue. Should other symptoms of systemic toxicity occur, the signs are anticipated to be similar in nature to those following the administration of local anaesthetics by other routes of administration. Local anaesthetic toxicity is manifested by symptoms of nervous system excitation and, in severe cases, central nervous and cardiovascular depression. Severe neurological symptoms (convulsions, CNS depression) must be treated symptomatically by respiratory support and the administration of anticonvulsive drugs;
circulatory signs are treated in line with recommendations for resuscitation.

Since the rate of absorption from intact skin is slow, a patient showing signs of toxicity should be kept under observation for several hours following emergency treatment.

5

PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties Pharmacotherapeutic group: Local anaesthetics ATC Code: N01B B20 EMLA Cream provides dermal analgesia. The depth of analgesia depends upon the application time and the dose. EMLA causes transient local peripheral vasoconstriction or vasodilation at the treated area. In patients with atopic dermatitis, a similar but shorter vascular reaction is seen, with erythema occurring after 30-60 minutes, indicating more rapid absorption through the skin (see section 4.5 Special precautions and special warnings for use). Paediatric population Clinical safety studies Methaemoglobin formation after the use of EMLA in term infants was studied with the aim to establish the safety of 1 g EMLA Cream 5%. Forty-seven neonates and infants, aged 0-3 months, with a post conceptual age of 37 weeks were included in a double blind, randomized, placebo-controlled study. Methaemoglobin concentrations before treatment with EMLA and placebo were in the range 0.67-1.57% and 0.501.53%, respectively. After treatment with 1 g EMLA/placebo for 60-70 min methaemoglobin concentrations were 0.50-2.53% for EMLA and 0.50-1.53% for placebo. From 3.5 to 13 h after application the concentrations were significantly higher with EMLA than with placebo, but were clinically insignificant. One sample, in the EMLA group (2.53%), had a methaemoglobin concentration above the reference value of 2%. Altogether, data from eleven clinical studies in neonates and infants showed that peak methaemoglobin concentrations occur about 8 hours after epicutaneous EMLA administration, are clinically insignificant with recommended dosage, and return to normal values after about 12-13 hours. Methaemoglobin formation is related to the cumulative amount of prilocaine percutaneously absorbed, and may therefore increase with prolonged application times of EMLA. Physiological methaemoglobin concentrations in both paediatric patients and adults are normally maintained below 2%. A major increase in methaemoglobin (to a concentration of 25-30%) will cause signs and symptoms of hypoxaemia. In neonates elevated methaemoglobin levels up to 56% are not regarded as clinically significant. Circumcision In two randomized, double-blind, placebo-controlled studies in full-term neonates aged 1 to 4 days EMLA Cream (0.5 or 1 g) was applied on the prepuce for one hour before circumcision, covered with an occlusive dressing. In the study using 0.5 g EMLA there was no significant differences with placebo in assessment of pain performed by evaluating facial expressions or heart rate, respiratory rate, oxygen saturation, nor in general skin colour. EMLA Cream (1 g) significantly reduced the pain during parts of the circumcision procedure, as demonstrated by less facial activity, reduction in duration of cry and

lower heart rates. No differences were found for oxygen saturation, respiratory rate and Neonatal Infant Pain Scale (NIPS) which includes facial expression, cry, breathing pattern and state of arousal. Vaccination Two randomized double-blind, placebo-controlled studies in infants and neonates looked at anaesthetic efficacy of EMLA Cream in vaccinations and the effect on the immunogenicity of live vaccines. The first study used EMLA Cream prior to subcutaneous measles-mumps-rubella vaccine, in patients aged 12-15 months, where 1g of cream was applied for 60-180 minutes. EMLA significantly reduced vaccination pain versus placebo, demonstrated by difference between the pre- and post-vaccination total score on the Modified Behavioural Pain Scale (MBPS - includes measurement of facial expression, cry and body movement). No difference versus placebo was seen with the separate assessment of proportion of patients that cry and duration of cry. The second used EMLA Cream prior to intramuscular diptheria-pertussis-tetanusinactivated poliovirus-Haemophilus influenzae b or Hepatitis B vaccines in patients aged 0-6 months, where 1 or 2g of cream was applied to patients aged 0-4 and 6 months respectively, for 60-180 minutes. EMLA significantly reduced vaccination pain versus placebo, demonstrated as above, for the 6 month-old group, however in the 0-4 month old group there was high variation in treatment response. In the 2 and 4 month-old groups, EMLA gave reduced pain versus placebo, however statistical significance was not shown (p=0.120 and 0.225 respectively). Within both studies, the use of EMLA did not affect mean antibody titres, rate of seroconversion, or the proportion of patients achieving protective or positive antibody titres post immunization, as compared to placebo treated patients.

5.2

Pharmacokinetic properties Systemic absorption of lidocaine and prilocaine from EMLA Cream is dependent upon the dose, application time, and the thickness of the skin, which varies between different areas of the body. Intact skin: In order to provide reliable dermal analgesia, EMLA Cream should be applied under an occlusive dressing for at least 1 hour. The duration of analgesia after an application time of 1-2 hours is at least 2 hours after removal of the dressing. After the application of EMLA cream to intact male genital skin for 15 minutes (median 1g), plasma concentrations of lidocaine and prilocaine (mean 6.6 nanogram/ml and 4.1 nanogram/ml) were reached after approximately 1.5 hours.

After application to the thigh in adults (60 g cream/400 cm2 for 3 hours) the extent of absorption was approximately 5% of lidocaine and prilocaine. Maximum plasma concentrations (mean 0.12 and 0.07 g/ml) were reached approximately 2-6 hours after the application. The extent of systemic absorption was approximately 10% following application to the face (10 g/100 cm2 for 2 hours). Maximum plasma levels (mean 0.16 and 0.06 g/ml) were reached after approximately 1.5-3 hours. Genital mucosa: Absorption from the genital mucosa is more rapid than after application to the skin. After the application of 10 g EMLA Cream for 10 minutes to vaginal mucosa maximum plasma concentrations of lidocaine and prilocaine (mean 0.18 micrograms/ml and 0.15 micrograms/ml respectively) were reached after 20-45 minutes. Paediatric population Following the application of 1 g EMLA Cream in infants/neonates below 3 months of age, to approx 10 cm2 for one hour, the maximum plasma concentrations of lidocaine and prilocaine were 0.135 micrograms/ml and 0.107 micrograms/ml respectively. Following the application of 2 g EMLA Cream in infants between 3 and 12 months of age, to approx 16 cm2 for four hours, the maximum plasma concentrations of lidocaine and prilocaine were 0.155 micrograms/ml and 0.131 micrograms/ml respectively. Following the application of 10 g of EMLA Cream in children between 2 and 3 years of age, to approx 100 cm2 for two hours, the maximum plasma concentrations of lidocaine and prilocaine were 0.315 micrograms/ml and 0.215 micrograms/ml respectively. Following the application of 10-16 g EMLA Cream in children between 6 and 8 years of age, to approx 100-160 cm2 for two hours, the maximum plasma concentrations of lidocaine and prilocaine were 0.299 micrograms/ml and 0.110 micrograms/ml respectively.

5.3

Preclinical safety data Lidocaine and prilocaine are well established active ingredients. Genotoxicity tests with lidocaine showed no evidence of mutagenic potential. A metabolite of lidocaine, 2,6-xylidine, showed weak evidence of activity in some genotoxicity tests. The metabolite 2,6-xylidine has been shown to have carcinogenicity potential in preclinical toxicological studies evaluating chronic exposure. Risk assessments comparing the calculated maximum human exposure from intermittent use of lidocaine, with the exposure used in preclinical studies, indicate a wide margin of safety for clinical use.

6. 6.1.

PHARMACEUTICAL PARTICULARS List of excipients Polyoxyethylene hydrogenated castor oil, Carbomer 974P, sodium hydroxide and water purified.

6.2.

Incompatibilities None known.

6.3.

Shelf life 3 years.

6.4.

Special precautions for storage Do not store above 30C, do not freeze.

6.5

Nature and contents of container Pre-medication pack containing 5 x 5 g tubes EMLA and 12 occlusive dressings. Pack containing 1 x 5 g tube of EMLA and 2 occlusive dressings. 1 x 30 g tube with enclosed spatula. 1 x 5 g tube.

6.6.

Instructions for use/handling Not applicable.

7.

MARKETING AUTHORISATION HOLDER AstraZeneca UK Limited 600 Capability Green Luton LU1 3LU

United Kingdom

8.

MARKETING AUTHORISATION NUMBER(S) PL 17901/0120

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 05th July 2002

10

DATE OF REVISION OF THE TEXT
25/03/2013